{"denoms":[{"counts":[{"groupId":"BG000","value":"161"}],"units":"Participants"}],"groups":[{"description":"All participants in this study received both study drugs and were therefore analysed together as a single treatment arm.\n\nParticipants receiving the different regimens were not analysed separately by regimen, as the study was designed to assess the safety of the combination study treatment.\n\nThe study included N=161 participants who received both acalabrutinib and pembrolizumab and are summarized together (from First stage safety lead-in and Second stage expansion). Stage 3 (additional expansion in subjects with Myelofibrosis) was planned but not conducted.","id":"BG000","title":"Acalabrutinib + Pembrolizumab"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"14.6","value":"62.4"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"63"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"98"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"11"}]}],"title":"Hispanic or Latino"},{"categories":[{"measurements":[{"groupId":"BG000","value":"148"}]}],"title":"Not Hispanic or Latino"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}],"title":"Not Reported"}],"paramType":"NUMBER","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}]}],"title":"American Indian or Alaska Native"},{"categories":[{"measurements":[{"groupId":"BG000","value":"4"}]}],"title":"Asian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"5"}]}],"title":"Black or African American"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}],"title":"Native Hawaiian or Other Pacific Islander"},{"categories":[{"measurements":[{"groupId":"BG000","value":"141"}]}],"title":"White"},{"categories":[{"measurements":[{"groupId":"BG000","value":"9"}]}],"title":"Not Reported"}],"paramType":"NUMBER","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"161"}]}],"title":"USA"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"Participants"}],"populationDescription":"All participants in this study received both study drugs and were therefore analyzed together as a single treatment arm. Participants receiving the different regimens were not analyzed separately by regimen, as the study was designed to assess the safety of the combination study treatment."}